Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of intravenous S 81694 in adults with advanced or metastatic solid tumors
NL-OMON47049Phase 1Active, not recruiting
- Sponsor
- Servier
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of s 81694 in Nonhematologic neoplasms, sponsored by Servier. Primary endpoint: Dose-limiting toxicities during first cycle. Started Dec 2015; status: active, not recruiting.
02
Drugs
s 81694
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON47049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47049.